Lv21
134 积分 2021-02-25 加入
The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer
1小时前
待确认
The pharmacokinetics of capmatinib and its efficacy in non-small cell lung cancer treatment: a narrative review
1小时前
求助中
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
2小时前
已完结
Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial
3小时前
已完结
PROTAC 2.0: Expanding the frontiers of targeted protein degradation
11天前
已完结
Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
11天前
已完结
Evolving roles of MET as a therapeutic target in NSCLC and beyond
11天前
已完结
Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
13天前
已完结
A phase II, open label, single-arm study on the efficacy of cabozantinib in patients with advanced/metastatic nonsmall cell lung cancer harboring MET exon 14 alterations who developed acquired resistance to tepotinib or capmatinib (CAPTURE trial)
13天前
已完结
Capmatinib inMETExon 14–Mutated orMET-Amplified Non–Small-Cell Lung Cancer
15天前
已完结
皖公网安备34019202002308
